Cencora (COR) Q2 FY25 earnings call

Cencora delivered strong Q2 FY25 results, primarily driven by robust performance in its U.S. Healthcare Solutions segment, leading to a raise in full-year adjusted EPS and operating income guidance. The company continues to leverage its pharmaceutical-centric strategy, focusing on specialty markets and expanding value-added services, despite facing headwinds in its International segment due to subdued clinical trial activity.